E2007

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Migraine Prophylaxis

Conditions

Migraine Prophylaxis

Trial Timeline

Jan 1, 2005 → Jun 1, 2006

NCT ID

NCT00154063

About E2007

E2007 is a phase 2 stage product being developed by Eisai for Migraine Prophylaxis. The current trial status is completed. This product is registered under clinical trial identifier NCT00154063. Target conditions include Migraine Prophylaxis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03201900	Phase 3	Completed	Jun 28, 2017	Jul 27, 2020	Partial Onset Seizures
NCT02116907	Phase 1	Completed	May 1, 2014	Sep 1, 2014	Healthy Subjects
NCT00849212	Phase 2	Completed	Apr 1, 2009	Nov 1, 2009	Refractory Partial Seizures
NCT00592904	Phase 2/3	Completed	Jan 1, 2008	Jul 1, 2011	Neuralgia
NCT00451633	Phase 2	Withdrawn	Mar 1, 2007	—	Parkinson's Disease
NCT00427011	Phase 2	Terminated	Feb 1, 2007	Apr 1, 2008	Parkinson's Disease
NCT00360412	Phase 3	Terminated	Oct 1, 2006	Apr 1, 2008	Parkinson's Disease
NCT00286897	Phase 3	Completed	Feb 1, 2006	Aug 1, 2007	Parkinson's Disease
NCT00165789	Phase 2	Completed	Sep 1, 2005	Sep 1, 2006	Parkinson's Disease
NCT00154063	Phase 2	Completed	Jan 1, 2005	Jun 1, 2006	Migraine Prophylaxis

Competing Products

20 competing products in Migraine Prophylaxis

See all competitors

Product	Company	Stage	Hype Score
ABP-450	AEON Biopharma	Phase 2	44
Lasmiditan + Placebo	Eli Lilly	Phase 3	77
Placebo + LY2300559	Eli Lilly	Phase 2	52
lasmiditan 200 mg + Sumatriptan + matching placebo	Eli Lilly	Phase 1	33
ABP-450 + Placebo	AEON Biopharma	Phase 2	44
Lasmiditan + Placebo	Eli Lilly	Phase 2	52
Ketorolac + Prochlorperazine + Diphenhydramine	Assertio Holdings	Phase 2	44
Galcanezumab + Erenumab	Eli Lilly	Approved	85
Aricept (donepezil hydrochloride)	Eisai	Phase 2	52
Galcanezumab + Rimegepant + Placebo + Placebo	Eli Lilly	Approved	85
Galcanezumab + Placebo	Eli Lilly	Phase 3	77
Lasmiditan + Placebo	Eli Lilly	Phase 2	52
Galcanezumab + Placebo	Eli Lilly	Phase 3	77
Lasmiditan	Eli Lilly	Phase 3	77
Galcanezumab Prefilled Syringe + Placebo	Eli Lilly	Phase 2	52
Emgality 120 MG in 1 ML Prefilled Syringe	Eli Lilly	Approved	85
Galcanezumab	Eli Lilly	Pre-clinical	23
Galcanezumab + Placebo	Eli Lilly	Phase 3	77
Galcanezumab + Placebo	Eli Lilly	Phase 2	52
LY2590443 + Placebo injection + Sumatriptan + Placebo capsule	Eli Lilly	Phase 2	52

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved